Continuing to strengthen FDA's science approach to emerging technologies

Emerging technologies result when advances and innovation in technology lead to discoveries. Often emerging technologies stimulate novel research in medical product development that contribute to new approaches to manufacturing and can improve the quality of products. By supporting investments in agency coordination, staff training and professional development, regulatory science research, stakeholder engagement, and enhancing opportunities for expert input, the U.S. Food and Drug Administration plays a critical role in translating innovations into novel safe and effective medical products that improve the public health.

Graphical AbstractThe U.S. Food and Drug Administration's (FDA) ability to support the responsible development of emerging technology products requires knowledge and understanding of science, active engagement of FDA's expert scientific staff, and building a strong infrastructure (FDA's science capacity) to guide science-based and science-led decision making. In this article, we discuss emerging technologies and a few Agency activities that help facilitate the development of products derived from emerging technologies including: 1) establishing lines of communication; 2) coordinating and making transparent agency activities; 3) creating opportunities for staff training and professional development; 4) supporting regulatory science research; and 5) engaging external stakeholders.Figure optionsDownload high-quality image (135 K)Download as PowerPoint slide